PP
VIGL

Paloma Partners’s Vigil Neuroscience VIGL Stock Holding History

Paloma Partners’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16,609
Closed -$66.4K – 1705
2024
Q2 		$66.4K Buy
+16,609
New +$56.8K ﹤0.01% 1123

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Paloma Partners's VIGL Position: Q3 2024 in Review

Paloma Partners sold out of Vigil Neuroscience (VIGL) in Q3 2024, closing a stake of 16,609 shares — an estimated $66.4K sold.

Paloma Partners first reported a position in VIGL in Q2 2024 and held it in 1 quarter. The position peaked at $66.4K in Q2 2024. 52 funds tracked by Wall St. Rank hold VIGL as of Q3 2024.

  • Paloma Partners reported no remaining Vigil Neuroscience position as of Q3 2024 after selling out during the quarter.
  • Paloma Partners sold 16,609 Vigil Neuroscience shares in Q3 2024, an estimated $66.4K.
  • Paloma Partners first reported a position in Vigil Neuroscience in Q2 2024 and held it in 1 quarter.
  • Paloma Partners's Vigil Neuroscience position peaked at $66.4K in Q2 2024.
  • 52 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.